CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 4 Open-market buy 10% owner bought 4,000 shares at an average $0.57 ($2,277)
- 4 Open-market buy 10% owner bought 5,000 shares at $0.81 ($4,050)
- 4 Open-market buy 10% owner bought 43,000 shares at an average $0.86 ($36,773)
- 10-Q Report Quarterly Report
- 4 Insider Changes in Ownership
- 4 Insider Changes in Ownership
- 4 Insider Changes in Ownership
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 1,000 shares at $1.29 ($1,289)
- 8-K Event Regulation FD disclosure
- 4 Other acquisition 10% owner acquired 933,334 shares (other)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy 10% owner bought 1,000 shares at $1.13 ($1,130)
- 4 Open-market buy 10% owner bought 6,000 shares at $1.19 ($7,136)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 2,000 shares at $1.23 ($2,467)
- 4 Open-market buy 10% owner bought 1,000 shares at $1.43 ($1,429)
- 8-K Event Regulation FD disclosure
- 4 Open-market buy 10% owner bought 3,500 shares at $1.19 ($4,153)
- 8-K Event Regulation FD disclosure
Page 10 of 20 · 398 filings